Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS: NWBO · Delayed Price · USD
0.460
-0.005 (-1.08%)
May 1, 2024, 3:59 PM EDT - Market closed
Northwest Biotherapeutics Revenue
In the year 2023, Northwest Biotherapeutics had annual revenue of $1.93M with 14.80% growth. Revenue in the quarter ending December 31, 2023 was $445.00K, a -25.46% decrease year-over-year.
Revenue (ttm)
$1.93M
Revenue Growth
+14.80%
P/S Ratio
284.61
Revenue / Employee
$77,280
Employees
25
Market Cap
549.87M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.93M | 249.00K | 14.80% |
Dec 31, 2022 | 1.68M | 678.00K | 67.46% |
Dec 31, 2021 | 1.01M | -286.00K | -22.15% |
Dec 31, 2020 | 1.29M | -1.12M | -46.43% |
Dec 31, 2019 | 2.41M | 2.00M | 484.95% |
Dec 31, 2018 | 412.00K | 76.00K | 22.62% |
Dec 31, 2017 | 336.00K | -287.00K | -46.07% |
Dec 31, 2016 | 623.00K | -1.12M | -64.17% |
Dec 31, 2015 | 1.74M | 285.00K | 19.60% |
Dec 31, 2014 | 1.45M | 645.00K | 79.73% |
Dec 31, 2013 | 809.00K | 37.00K | 4.79% |
Dec 31, 2012 | 772.00K | 762.00K | 7,620.00% |
Dec 31, 2011 | 10.00K | - | - |
Dec 31, 2010 | 10.00K | - | - |
Dec 31, 2009 | 10.00K | - | - |
Dec 31, 2008 | 10.00K | - | - |
Dec 31, 2007 | 10.00K | -790.00K | -98.75% |
Dec 31, 2006 | 800.00K | 676.00K | 545.16% |
Dec 31, 2005 | 124.00K | -266.00K | -68.21% |
Dec 31, 2004 | 390.00K | -139.00K | -26.28% |
Dec 31, 2003 | 529.00K | 520.00K | 5,777.78% |
Dec 31, 2002 | 9.00K | -120.45K | -93.05% |
Dec 31, 2001 | 129.45K | -26.52K | -17.00% |
Dec 31, 2000 | 155.96K | -54.04K | -25.73% |
Dec 31, 1999 | 210.00K | -180.00K | -46.15% |
Dec 31, 1998 | 390.00K | -90.00K | -18.75% |
Dec 31, 1997 | 480.00K | 250.00K | 108.70% |
Dec 31, 1996 | 230.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
NWBO News
- 5 weeks ago - Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors - PRNewsWire
- 3 months ago - Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification - PRNewsWire
- 4 months ago - Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma - PRNewsWire
- 5 months ago - Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application - PRNewsWire
- 7 months ago - Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application - PRNewsWire
- 8 months ago - Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board - PRNewsWire
- 8 months ago - Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application - PRNewsWire
- 1 year ago - Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility - PRNewsWire